Japan's Astellas to Buy U.S. Drugmaker OSI for $4 Bil.
By wchung | 21 Mar, 2026
Astellas Pharma Inc., Japan’s No. 2 drug maker, said Monday it will buy U.S. cancer drug company OSI Pharmaceuticals Inc. for $4 billion in cash in a bid to expand its cancer drug business worldwide.
Astellas said it will pay $57.50 per OSI share, up from $52 the Japanese company had offered earlier. The transaction will be completed within a month.
The acquisition is part of Astellas’ drive to expand its cancer drug business worldwide. OSI’s drugs include Tarceva, for lung cancer, which generated $1.2 billion in global sales last year.
The Japanese maker said it hopes to jointly develop cancer drugs with OSI.
Apart from cancer, OSI focuses on oncology, diabetes and obesity treatments.
TOKYO (AP)
Articles
- Airports Step up to Feed Unpaid TSA Workers
- Don Struggles for a Face-Saving Exit from a Self-Created Nightmare
- OpenAI to Double Workforce to 8,000 by End of 2026
- BTS Comeback Concert Shuts Down Central Seoul
- United Cuts 5% of Flights, Plans for $175 per Barrel Oil
- Softbank, AEP to Build Massive Ohio Gas Power Plant, Data Center
- Musk's Liable to Twitter Shareholders, Damages to Be Determined
- Next-Gen Parenting for Success in an Automating World—for Yourself and Your Kids
- MLB’s Opening Day Odds and Value Picks
- Attack on Harvard Renewed with Another Antisemitism Suit